The 12th Immuno-Oncology Summit 2024 was held in Philadelphia, PA on August 7-9, 2024. The annual event serves as a vital platform for exchanging high-quality research and fostering collaboration in the ever-evolving landscape of immuno-oncology. Topics discussed included:
Bispecific Antibodies for Cancer Immunotherapy
Advances in CAR T Therapy
Therapeutic Cancer Vaccines
Emerging Tech for IO Targeting and Discovery
Emerging Cell-Based Immunotherapies
Tumor Microenvironment
→ Biointron’s Highlighted Points:
1. Bispecific Breakthroughs: Reimagining Design, Manufacturing, & Safety
Creating cancer-specific neoantigens by exploiting covalent inhibitors and targeting them with bispecific antibodies unites targeted and immune therapies. (NYU Grossman School of Medicine)
Adapting T cell engagers to target the massive intracellular proteome has been challenging due to low cell-surface density antigen presentation. Geometry plays an important role in efficiently targeting low density cell-surface pMHC, rather than avidity. (AstraZeneca)
The humanized trispecific antibody TAVO412, has two distinct anti-EGFR nanobody domains, an anti-cMet Fab arm, and an anti-VEGF ScFv. It infiltrates solid tumor stromal barriers to treat patients with gastric, TNBC, and pancreatic cancer subtypes. (Tavotek Biotherapeutics)
2. Breaking Barriers in CAR T: Engineering, Synergistic Strategies, & Beyond
iPSC-derived CD8ab CAR T cells: Early TCR or CAR expression promotes the acquisition of an innate phenotype, which is averted by timed and calibrated CAR expression. (Memorial Sloan Kettering Cancer Center)
Proposed precision medicine approach for B-cell malignancies using CAR T cells involves engineering T cells with a CAR that recognizes the IGHV4-34 B Cell Receptor to specifically eliminate malignant B-cells. (University of Pennsylvania)
Integrated Circuit T Cells (ICTs), a novel engineered T cell design, incorporates multiple functionalities for a promising approach to achieve more precise targeting of solid tumors. (Arsenal Bio)
3. Innovative Vaccine Strategies to Advance Cancer Immunotherapy
A novel personalized therapeutic mRNA lipid nanoparticle vaccine shows efficacy in brain, neck, and oral cancer preclinical and clinical trials. (Cleveland Clinic)
Long-read sequencing allows us to resolve a broader spectrum of protein altering genomic events which serve as a richer basis for neoantigen discovery, versus short-read exome sequencing. (University of North Carolina at Chapel Hill)
Non-invasive mRNA delivery via stabilized, lung-optimized lipid nanoparticles for pulmonary applications, and the enhancement of immune responses in mRNA vaccines through integration of multiple, novel adjuvants. (Broad Institute)
4. Unlocking Precision IO: Innovative Tools, Targets, & Solutions
CRISPR screening in immunosuppressive tumor-associated macrophages (TAMs) identifies novel targets that reprogram TAMs into immunostimulatory macrophages, leading to abrogation of established tumors. (Weill Cornell Medicine)
Predicting therapy outcomes with autoantibody biomarkers in melanoma has shown promising results, holding great potential to personalize cancer therapy for more effective and safer treatments (NYU Grossman School of Medicine)
Casdozokitug, a potent and selective anti-IL-27 antibody has demonstrated immune activation and single-agent tumor response, overcoming PD-1 resistance in clinical trials. (Coherus Biosciences
Thank you for visiting us at our booth at Immuno-Oncology Summit 2024 to learn about our services! We had a great time connecting with you and understanding how we can help you achieve antibody development. Our expert team would be happy to answer any follow-up questions. Feel free to email us at info@biointron.com!
